[1]王　蕾,王　丹,李汝珂,等.“五个时刻法”延续用药指导在慢性乙型肝炎长期抗病毒治疗中的应用价值[J].新乡医学院学报,2021,38(6):526-530.[doi:10.7683/xxyxyxb.2021.06.006]
　WANG Lei,WANG Dan,LI Ruke,et al.Application value of "5-moment method" continuous medication guidance in long-term antiviral therapy of chronic hepatitis B[J].Journal of Xinxiang Medical University,2021,38(6):526-530.[doi:10.7683/xxyxyxb.2021.06.006]
点击复制

“五个时刻法”延续用药指导在慢性乙型肝炎长期抗病毒治疗中的应用价值
分享到：

《新乡医学院学报》[ISSN:1004-7239/CN:41-1186/R]

卷:
38
期数:
2021年6
页码:
526-530
栏目:
临床研究
出版日期:
2021-06-05

文章信息/Info

Title:
Application value of "5-moment method" continuous medication guidance in long-term antiviral therapy of chronic hepatitis B
作者:
王　蕾; 王　丹; 李汝珂; 李长安; 赵巍峰
（新乡医学院第三附属医院感染性疾病科，河南　新乡　453000）
Author(s):
WANG Lei; WANG Dan; LI Ruke; LI Chang′an; ZHAO Weifeng
(Department of Infectious Diseases,the Third Affiliated Hospital of Xinxiang Medical University,Xinxiang 453000,Henan Province,China)
关键词:
慢性乙型肝炎; 抗病毒治疗; 用药指导; 服药依从性; 自我效能
Keywords:
chronic hepatitis Bantiviral therapymedication guidancemedication complianceself-efficacy
分类号:
R453
DOI:
10.7683/xxyxyxb.2021.06.006
文献标志码:
A
摘要:
目的　探讨“五个时刻法”延续用药指导在慢性乙型肝炎（CHB）长期抗病毒治疗中的应用价值。方法　选择2017年7月至2019年6月新乡医学院第三附属医院收治的102例CHB患者为研究对象，按照入院时间将患者分为观察组（n=50）和对照组（n=52）。2组患者均接受长期抗病毒治疗，对照组患者实施常规延续性用药指导，观察组患者实施“五个时刻法”延续性用药指导，对2组患者干预前及干预3、6、12个月时的Morisky用药依从性量表（MMAS-8）评分、服药依从率、一般自我效能感量表（GSES）评分、健康教育知识掌握程度进行比较；所有患者随访 1 a，观察干预3、6、9、12个月时的复查率。结果　干预前2组患者MMAS-8、GSES评分比较差异无统计学意义（P＞0.05），2组患者干预3、6、12个月时 MMAS-8、GSES评分均显著高于干预前（P＜0.05），干预3、6、12个月时观察组患者MMAS-8、GSES评分均显著高于对照组（P＜0.05）。干预前及干预3、6、12个月时，观察组患者服药依从率分别为24.00%（12/50）、86.00%（43/50）、90.00%（45/50）、92.00%（46/50），对照组患者服药依从率分别为28.85%（15/52）、67.31%（35/52）、69.23%（36/52）、71.15%（37/50）；干预前2组患者服药依从率比较差异无统计学意义（P＞0.05）；2组患者干预3、6、12个月时服药依从率显著高于干预前（P＜0.05）；干预3、6、12个月时，观察组患者服药依从率显著高于对照组（P＜0.05）。干预前2组患者健康教育知识评分比较差异无统计学意义（P＞0.05），2组患者干预3、6、12个月时健康教育知识评分均显著高于干预前（P＜0.05），干预3、6、12个月时观察组患者健康教育知识评分均显著高于对照组（P＜0.05）。干预3、6、9、12个月时，观察组患者复查率分别为96.00%（48/50）、100.00%（50/50）、94.00%（47/50）、98.00%（49/50），对照组患者复查率分别为82.69%（43/52）、80.77%（42/52）、76.92%（40/52）、82.69%（43/52），干预3、6、9、12个月时观察组患者复查率均显著高于对照组（P＜0.05）。结论　“五个时刻法”延续用药指导有助于提高CHB患者自我效能、用药知识认识、服药依从性，对CHB长期抗病毒治疗有积极作用。
Abstract:
Objective　To investigate the application value of "5-moment method" continuous medication guidance in long-term antiviral therapy of chronic hepatitis B (CHB).Methods　　A total of 102 patients with CHB admitted to the Third Affiliated Hospital of Xinxiang Medical University from July 2017 to June 2019 were selected as the study subjects.The patients were divided into observation group (n=50) and control group (n=52) according to the admission time.The patients in the two groups received long-term antiviral therapy.The patients in the control group were given routine continuous medication guidance,while the patients in the observation group were given "5-moment method" continuous medication guidance.The Morisky medication adherence scale-8 (MMAS-8) score,medication compliance rate,general self-efficacy scale (GSES) score and the acquisition of health education knowledge were compared between the two groups at pre-intervention and 3,6,12 months of intervention.All patients were followed up for one year,and the reexamination rate at 3,6,9 and 12 months of intervention were observed.Results　There was no significant difference in the MMAS-8 and GSES scores between the two groups before intervention (P＞0.05).The MMAS-8 and GSES scores at 3,6 and 12 months of intervention were significantly higher than those before intervention in the two groups (P＜0.05).The MMAS-8 and GSES scores in the observation group were significantly higher than those in the control group at 3,6 and 12 months of intervention (P＜0.05).Before intervention and 3,6,12 months after intervention,the medication compliance rate in the observation group was 24.00% (12/50),86.00% (43/50),90.00% (45/50),92.00% (46/50),respectively;while that in the control group was 28.85% (15/52),67.31% (35/52),69.23% (36/52),71.15% (37/50),respectively.There was no significant difference in medication compliance rate between the two groups before intervention (P＞0.05).The medication compliance rate at 3,6 and 12 months of intervention were significantly higher than that before intervention in the two groups (P＜0.05).At 3,6 and 12 months of intervention,the medication compliance rate in the observation group was significantly higher than that in the control group (P＜0.05).There was no significant difference in the health education knowledge score between the two groups before intervention (P＞0.05).The health education knowledge scores at 3,6 and 12 months of intervention were significantly higher than those before intervention in the two groups (P＜0.05).At 3,6 and 12 months of intervention,the health education knowledge score in the observation group was significantly higher than that in the control group (P＜0.05).At 3,6,9 and 12 months of intervention,the reexamination rate in the observation group was 96.00% (48/50),100.00% (50/50),94.00% (47/50) and 98.00% (49/50),respectively;which in the control group was 82.69% (43/52),80.77% (42/52),76.92% (40/52) and 82.69% (43/52),respectively.The reexamination rate in the observation group was significantly higher than that in the control group at 3,6,9 and 12 months of intervention (P＜0.05).Conclusion　The "5-moment method" continuous medication guidance is helpful to improve the self-efficacy,medication knowledge and medication compliance of CHB patients.It plays a positive role in long-term antiviral therapy of CHB.

参考文献/References:

［1］　CUI F,SHEN L,LI L,et al.Prevention of chronic hepatitis B after 3 decades of escalating vaccination policy,China［J］.Emerg Infect Dis,2017,23(5):765-772.
［2］　PAPATHEODORIDI M,PAPATHEODORIDIS G.Emerging diagnostic tools to decide when to discontinue nucleos(t)ide analogues in chronic hepatitis B［J］.Cells,2020,9(2):493-509.
［3］　BONI C,VECCHI A,ROSSI M,et al.TLR7 agonist increases responses of hepatitis B virus-specific T cells and natural killer cells in patients with chronic hepatitis B treated with nucleos(t)ide analogues［J］.Gastroenterology,2018,154(6):1764-1777.
［4］　韩宗儒，闵晓春，沈启刚，等.慢性乙型肝炎患者服用核苷（酸）类药物的依从性调查及其影响因素分析［J］.肝脏，2020，25（11）：16-20.
［5］　杜晓娜，田红卫，吴惠萍，等.孕中晚期乙肝患者抗病毒治疗服药依从性及影响因素［J］.中国医药导报，2018，15（23）：77-81.
［6］　王贵强，王福生，成军，等.慢性乙型肝炎防治指南：2015年更新版［J］.临床肝胆病杂志，2015，31（12）：1941-1960.
［7］　侯凯旋，闫素英.慢病患者药物依从性量表的研究［J］.中国医院药学杂志，2018，38（2）：192-196.
［8］　翁艳君，赵豫梅，刘伟军，等.中文版8条目Morisky服药依从性量表在2型糖尿病患者中的信效度评价及应用研究［J/CD］.中华临床医师杂志：电子版，2018，12（8）：445-450.DOI：10.3877/cma.j.issn.1674-0785.2018.08.004.
［9］　JNSSON T,HANSSON E E,THORSTENSSON C A,et al.The effect of education and supervised exercise on physical activity,pain,quality of life and self-efficacy:an intervention study with a reference group［J］.BMC Musculoskelet Disord,2018,19(1):198-209.
［10］　金佳瑶，张会君.中文版自我效能评定量表在社区居住老年人中应用的信效度研究［J］.中国全科医学，2017，20（29）：92-95.
［11］　邱海岩，于颖慧，陈海明.张家港市流动人口乙肝相关知识知晓率及健康教育需求调查分析［J］.现代预防医学，2018，45（7）：1315-1318.
［12］　KIKKERT M J,DEKKER J.Medication adherence decisions in patients with schizophrenia［J］.Prim Care Companion CNS Disord,2017,19(6):127-138.
［13］　吴小凤，李玉芳，张驰，等.慢性乙型肝炎患者核苷（酸）类似物抗病毒治疗依从性的影响因素分析［J］.临床肝胆病杂志，2019，35（10）：2194-2199.
［14］　CONN V S,RUPPAR T M.Medication adherence outcomes of 771 intervention trials:systematic review and meta-analysis［J］.Prev Med,2017,99(2):269-276.
［15］　朱正云，张婷婷，赵文海，等.153例慢性病毒性乙型肝炎患者疾病感知水平与服药依从性的相关性分析［J］.护理学报，2018，25（16）：38-41.
［16］　SILVA K,MILLER V A.Does self-efficacy mediate the link between impulse control and diabetes adherence［J］.J Pediatr Psychol,2020,45(4):445-453.
［17］　OSHOTSE C,ZULLIG L L,BOSWORTH H B,et al.Self-efficacy and adherence behaviors in rheumatoid arthritis patients［J］.Prev Chronic Dis,2018,15:E127-E137.
［18］　NFRDI L,NAKAMOTO K,SCHULZ P J.Is patient empowerment the key to promote adherence? A systematic review of the relationship between self-efficacy,health locus of control and medication adherence［J］.PLoS One,2017,12(10):e0182458.
［19］　王倩，赵伟.基于现代化健康教育方式对提高慢性乙型肝炎患者依从性的影响［J］.山西医药杂志，2020，49（21）：3022-3024.
［20］　王婷婷，赵晓燕，金拼拼，等.“5个时刻法”在慢性乙型肝炎抗病毒治疗管理中的应用［J］.中华现代护理杂志，2020，26（18）：2489-2493.

相似文献/References:

[1]何玉洁,袁翠云,石惠琴.苦参素联合拉米夫定治疗慢性乙肝疗效观察[J].新乡医学院学报,2003,20(01):040.
[2]刘朝阳,魏素云,于培龙.氧化苦参碱联合拉米夫定治疗慢性乙型肝炎疗效观察[J].新乡医学院学报,2003,20(01):041.
[3]何玉洁,袁翠云,石惠琴.苦参素联合拉米夫定治疗慢性乙肝疗效观察[J].新乡医学院学报,2003,20(01):040.
[4]刘朝阳,魏素云,于培龙.氧化苦参碱联合拉米夫定治疗慢性乙型肝炎疗效观察[J].新乡医学院学报,2003,20(01):041.
[5]吕福鸣,许青田,李蒙军.慢性乙型肝炎患者血清HBV DNA定量检测与抗原抗体模式的关系 [J].新乡医学院学报,2006,23(03):000.
[6]张高峰,翟自霞.大学新生慢性乙型肝炎患者心理健康状况分析[J].新乡医学院学报,2011,28(06):000.
[7]李银彩.血府逐淤汤联合干扰素对慢性乙型肝炎肝硬化患者肝纤维化及门静脉血流动力学的影响[J].新乡医学院学报,2012,29(08):615.
[8]向保云１,李红德１,徐江海１,等. 肿瘤坏死因子-α和白细胞介素-１β在慢性乙型肝炎和原发性肝癌患者血清及肝组织中的表达 [J].新乡医学院学报,2014,31(12):999.[doi:10.7683/xxyxyxb.2014.12.009]
[9]李长安,赵巍峰,刘淑媛,等.核苷类似物序贯联合聚乙二醇干扰素α-2b治疗乙型肝炎表面抗原低水平慢性乙型肝炎患者疗效观察[J].新乡医学院学报,2022,39(4):323.[doi:10.7683/xxyxyxb.2022.04.005]
　LI Changan,ZHAO Weifeng,LIU Shuyuan,et al.Effect of sequential combination of nucleoside analogues and pegylated interferon α-2b in the treatment of chronic hepatitis B patients with low level of hepatitis B surface antigen[J].Journal of Xinxiang Medical University,2022,39(6):323.[doi:10.7683/xxyxyxb.2022.04.005]
[10]冯新霞,赵巍峰.精细化临床护理路径在抗病毒药物治疗慢性乙型肝炎患者中的应用价值[J].新乡医学院学报,2022,39(6):583.[doi:10.7683/xxyxyxb.2022.06.017]
　FENG Xinxia,ZHAO Weifeng.Application value of refined clinical nursing pathway in the antiviral therapy of patients with chronic hepatitis B[J].Journal of Xinxiang Medical University,2022,39(6):583.[doi:10.7683/xxyxyxb.2022.06.017]

更新日期/Last Update: 2021-06-05